Considerations in dosage selection for third generation cephalosporins
- PMID: 1551290
- DOI: 10.2165/00003088-199222020-00004
Considerations in dosage selection for third generation cephalosporins
Abstract
Pharmacokinetic parameters of third generation cephalosporins vary widely, requiring different dosage regimens and adjustment methods for each agent. Although their antibacterial spectrum favours their usage in infections caused by aerobic Gram-negative organisms, due to their limited post-antibiotic effect against these organisms, dosage regimens should ensure that free drug concentrations at the site of infection remain above the minimum inhibitory concentration for as much of the dosage interval as possible in patients with normal host defence mechanisms and for the entire dosage interval in immunocompromised patients. Altered protein binding encountered in various disease states can affect both microbiological and pharmacokinetic properties especially for drugs with high protein binding. Since the concentrations at the site of action are often different from those in serum, a higher or lower range of dosages needs to be selected depending on the target site. Decreased renal function affects the elimination of most third generation cephalosporins, whereas the presence of hepatic disease does not generally necessitate dosage adjustment. Because of the complex age-related physiological changes in paediatric and elderly patients, dosage should be adjusted on the basis of the reported pharmacokinetic data in these populations. The usual recommended dose may or may not be optimal in a given condition depending on the complex interactions between pharmacokinetic, microbiological and other host factors.
Similar articles
-
[Review of oral cephalosporins. Basis for a rational choice].Medicina (B Aires). 1994;54(5 Pt 1):439-58. Medicina (B Aires). 1994. PMID: 7658980 Review. Spanish.
-
Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination.Pharmacotherapy. 2015 Jul;35(7):701-15. doi: 10.1002/phar.1609. Epub 2015 Jul 1. Pharmacotherapy. 2015. PMID: 26133315 Review.
-
A series of pharmacokinetic studies of ceftaroline fosamil in select populations: normal subjects, healthy elderly subjects, and subjects with renal impairment or end-stage renal disease requiring hemodialysis.J Clin Pharmacol. 2014 Jul;54(7):742-52. doi: 10.1002/jcph.265. Epub 2014 Jan 22. J Clin Pharmacol. 2014. PMID: 24431097 Clinical Trial.
-
[Cefoperazone and other third-generation cephalosporins].Antibiot Khimioter. 1992 Oct;37(10):52-4. Antibiot Khimioter. 1992. PMID: 1296538 Review. Russian. No abstract available.
-
[Antibiotic activities of cefpirome against fresh clinical isolates resistant to multiple drugs].Jpn J Antibiot. 1994 Feb;47(2):143-60. Jpn J Antibiot. 1994. PMID: 8151908 Japanese.
Cited by
-
Drug utilisation review (DUR) of the third generation cephalosporins. Focus on ceftriaxone, ceftazidime and cefotaxime.Drugs. 1995 Sep;50(3):423-39. doi: 10.2165/00003495-199550030-00002. Drugs. 1995. PMID: 8521766 Review.
-
Ceftriaxone. A pharmacoeconomic evaluation of its use in the treatment of serious infections.Pharmacoeconomics. 1994 Sep;6(3):249-69. doi: 10.2165/00019053-199406030-00009. Pharmacoeconomics. 1994. PMID: 10155268
-
Pharmacological properties of parenteral cephalosporins: rationale for ambulatory use.Drugs. 2000;59 Suppl 3:9-18; discussion 47-9. doi: 10.2165/00003495-200059003-00002. Drugs. 2000. PMID: 10845409 Review.
-
Clinical pharmacokinetics of cefotetan.Clin Pharmacokinet. 1994 Apr;26(4):248-58. doi: 10.2165/00003088-199426040-00002. Clin Pharmacokinet. 1994. PMID: 8013159 Review.
-
Pharmacokinetics of drugs used in critically ill adults.Clin Pharmacokinet. 1998 Jan;34(1):25-56. doi: 10.2165/00003088-199834010-00002. Clin Pharmacokinet. 1998. PMID: 9474472 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources